From Podium To Practice – Breast Cancer ESMO Part 9
In this forward-looking discussion, Dr. Wassim Mchayleh and Dr. Sara Tolaney explore the rapidly evolving role of antibody–drug conjugates (ADCs) in first-line metastatic triple-negative breast cancer (mTNBC). Dr. Tolaney highlights the significance of having both sacituzumab govitecan and datopotamab deruxtecan (dato-DXd) as standard-of-care options for PD-L1–negative disease, emphasizing differences in dosing schedules, toxicity profiles, and patient-centered decision-making. She reflects on how ADCs are reshaping outcomes in a historically difficult-to-treat population and offers practical guidance for community clinicians navigating these choices. Sponsored By Gilead.